Orum Therapeutics is at the forefront of developing innovative therapies through its proprietary Dual-Precision Targeted Protein Degradation (TPD²) technology. This approach combines the efficacy of targeted protein degraders with the precision of antibody delivery systems, allowing for the selective degradation of intracellular target proteins within cancer cells. By utilizing antibodies to deliver small molecule degraders specifically to tumor cells, Orum aims to enhance the potency, safety, and pharmacokinetics of these therapies. Their lead candidates, ORM-5029 and ORM-6151, exemplify this strategy, targeting proteins associated with various malignancies, including HER2-positive breast cancer and acute myeloid leukemia.

In addition to TPD², Orum has developed the Dual-Precision Targeted Protein Stabilization (TPS²) approach, which focuses on stabilizing specific proteins to enhance anti-tumor immune responses. This method employs antibody delivery to direct Cbl-b inhibitors to exhausted T cells within the tumor microenvironment, thereby blocking immunosuppressive signals and potentially improving the efficacy of cancer immunotherapies. Orum's innovative technologies not only expand the landscape of druggable targets but also pave the way for novel therapeutic classes, such as degrader-antibody conjugates (DACs), which are designed to improve bioavailability and therapeutic outcomes in cancer treatment.

United States

Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD² approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Boston, US and Daejeon, South Korea.

Orum Therapeutics

Company Details